The purchase by a 10% owner is a positive signal, but the dollar amount is small relative to market cap. Monitor for additional insider buying or company catalysts (e.g., pipeline updates, partnerships) that could drive further conviction.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 15 $9.92entry
- T+1 · 4mo ago −8.87%α −8.33% · $9.04
- T+5 · 4mo ago +1.01%α +1.99% · $10.02
- T+20 · 3mo ago +16.23%α +13.89% · $11.53
- T+60 · 6w ago −31.45%α −33.98% · $6.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
RA Capital Management, L.P., a director and 10% owner of Artiva Biotherapeutics, purchased 15,100 shares at $8.97 for a total of $135K on July 10, 2026. This is a standalone conviction buy by a major insider, signaling confidence in the company's prospects at current valuation.
Key Financial Metrics
Key Facts
- RA Capital Management (Director, 10% Owner) bought 15,100 shares at $8.97 for $135K on July 10, 2026.
- Total purchase value of $135K represents approximately 0.06% of Artiva's $221M market cap.
- Recent insider activity shows 6 buys totaling $1.7M in the last 30 days, indicating sustained insider confidence.
- Analyst consensus is 92% bullish (4 Strong Buy, 7 Buy, 1 Hold).
Financial Impact
Insider purchase of $135K, representing 0.06% of market cap.
Risk Factors
- The purchase amount ($135K) is small relative to market cap (0.06%), limiting its signaling power.
- Biotech sector volatility and binary pipeline events could overshadow insider buying.
- RA Capital may be averaging into a position rather than signaling a near-term catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001231919-26-000764 |
Track record
33 reports on ARTV
10 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers